Description

FABHALTA is a complement factor B inhibitor, indicated for:
• The treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).
• The reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. This indication is approved under accelerated approval based on
reduction of proteinuria. It has not been established whether FABHALTA slows kidney function decline in patients with IgAN.
Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.
• The treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.

Additional information

Brand	FABHALTA
Generic name	Iptacopan capsules
Form	Oral capsules
Strength	200mg
Packing	56's/Pack
Manufacturer	Novartis
Documents	Either PO or prescription
Storage	below 30°C temperature